摘要
目的探讨那格列奈治疗2型糖尿病的有效性与安全性。方法将2013年3月~2015年3月我院收治的69例2型糖尿病患者分为两组,实验组35例给予那格列奈治疗,对照组34例给予瑞格列奈治疗。结果评价序贯疗法治疗急性缺血性脑血管病的药物经济学价值。方法以我院2012年3月~2014年10月收治的80例急性缺血性脑血管病患者为研究对象,随机将其分为两组,各40例,对照组患者采取脑苷肌肽注射液治疗,观察组患者则行药物序贯治疗（先行脑苷肌肽注射液治疗,1周后改为丁苯酞软胶囊、消栓通络胶囊）,比较两组临床疗效及不良反应,同时行成本-效果药物经济学评价。结果观察组治疗总有效率90.0%,不良反应发生率5.0%,与对照组的95.0%、7.5%比较差异无统计学意义（P〉0.05）。另外,观察组成本/效果为131.9,对照组为178.9。结论序贯疗法治疗在保证临床疗效及安全性基础上,能明显降低急性缺血性脑血管病成本,药物经济学更佳。
Objective To evaluate the pharmacoeconomic value of sequential therapy in treatment of acute ischemic cerebralvascular disease Methods 80 cases of patients with acute ischemic cerebrovascular disease admitted into our hospital from March 2012 to October 2014 were selected as the research object and were randomly divided into two groups, 40 cases in each group. The control group received cattle encephalon glycoside injection while the patients in the observation group received medicine sequential therapy, namely, firstly took cattle encephalon glycoside and ignotin injection and then took butylphthalide soft capsules and Xiaoshuantongluo capsule a week later. The clinical efficacy and adverse reactions of two groups were compared and the the cost-effectivenesspharmacoeconomic evaluation was made at the same time. Results The total effective rate of observation group was 90% and the adverse reaction rate was 5%. There was no statistical significance compared with the rates of control group which were 95% and 7.5%（P〈0.05）. In addition, the cost / effect of the observation group was 131.9 while the control group 178.9. Conclusion Sequential therapy can reduce the cost of treating acute ischemic cerebrovascular disease on the basis of ensuring the clinical efficacy and safety significantly with better pharmacoeconomics
出处
《中国继续医学教育》
2015年第15期135-137,共3页
China Continuing Medical Education
关键词
序贯疗法
急性缺血性脑血管病
药物经济学
Sequential therapy
Acute ischemic cerebrovascular disease
Pharmacoeconomics
